Navigation Links
AutoImmune Inc. Files Certificate of Dissolution and Completes Sale of Colloral® Business; Trading of Common Stock to Cease After June 30, 2010
Date:6/30/2010

PASADENA, Calif., June 30 /PRNewswire-FirstCall/ -- AutoImmune Inc. (Pink Sheets: AIMM) today announced that it filed its Certificate of Dissolution with the Delaware Secretary of State on June 30, 2010 (the "Final Record Date"), in accordance with its previously announced Plan of Complete Liquidation and Dissolution. As a result of such filing, the company has closed its stock transfer books and will discontinue recording transfers of its common stock, except by will, intestate succession or operation of law effective at the close of business on the Final Record Date.  All liquidating distributions from AutoImmune after the Final Record Date will be made to stockholders of record on the Final Record Date pro rata according to their holdings of common stock as of the Final Record Date.

In furtherance of the company's Plan of Complete Liquidation and Dissolution, the company has completed a sale of the assets of the Colloral® business, the company's joint venture with Deseret Laboratories, Inc.  As part of the sale transaction and dissolution process, Colloral LLC was merged with and into AutoImmune.

As previously announced, AutoImmune's business activities are now limited to those necessary to preserve the value of its assets, wind up its business and affairs, and distribute its assets in accordance with the Plan of Complete Liquidation and Dissolution.

About AutoImmune Inc.

AutoImmune is a biopharmaceutical company that has focused on the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

website: http://www.autoimmuneinc.com


'/>"/>
SOURCE AutoImmune Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
2. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
3. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
4. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
5. Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies
6. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
7. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
8. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
9. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis instruments and consumables for the medical ... to discuss its financial results for the third quarter ... will be at 4:15 p.m. ET on Thursday, January ... the third quarter fiscal year 2017 after the market ...
(Date:1/19/2017)... January 19, 2017 Shire plc ... the U.S. Food and Drug Administration (FDA) has acknowledged ... Drug Application (NDA) for SHP465, a long-acting, triple-bead, mixed ... potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA ... June 20, 2017, the designated Prescription Drug User Fee ...
(Date:1/19/2017)... 19, 2017 While various ... about reducing the FDA,s regulatory strictness as a ... medical drug industry, many of the leading biotech ... trials and development of advanced drug treatments and ... recent developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 19, 2017 , ... Aerolib Healthcare Solutions ... Clinical and Regulatory education for Physicians, Physician Advisors, Case managers, Utilization Review ... of Disease Specific Documentation Improvement. , The Aerolib Learning Management System is ...
(Date:1/19/2017)... ... 19, 2017 , ... With the cold weather here, many people will have to clear snow ... clearing large amounts of snow, but they can be dangerous when used incorrectly. That’s why ... Commission for the proper use of snow blowers:, , When removing ...
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital media company ... Heart Association (AHA) to produce a three-part video series that uses humor to highlight ... of the launch of AHA’s Healthy For Good™ movement, which is designed to inspire ...
(Date:1/19/2017)... ... January 19, 2017 , ... WholeHealth is ... year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will be present Saturday ... clinic’s leading recovery program. , “We know it’s easy to get carried ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... recently provided a new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health ... facility were used to facilitate a recapitalization of MedPro led by Harren Equity ...
Breaking Medicine News(10 mins):